BFLXE .007^16%-FORM 8-K SECURITIES AND EXCHANGE

New Post Public Reply Private Reply Replies (0) Message Board
FLA

[b]BFLXE [/b].007^16%-FORM 8-K


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 21, 2012

Bioflamex Corporation
(Exact name of registrant as specified in its charter)

Nevada000-53712Pending
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)


Christiansvej 28, 2920 Charlottenlund, Denmark____________________
(Address of principal executive offices)(Zip Code)


Registrant’s telephone number, including area code: 646-233-1310


___________________________________________________
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

On June 21, 2012, the board of directors of Bioflamex Corp. (the “Company”) determined, upon advice of management, that the Company’s financial statements and related disclosures included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2011 and the Company’s Quarterly Reports on Form 10-Q for the periods ended May 31, 2011, August 31, 2011 and November 30, 2011 (the “Previously Issued Financial Statements”) should be restated because they contain errors as addressed in Financial Accounting Standards Board Accounting Standards Codification Topic 250, Accounting Changes and Error Corrections. Accordingly, the Previously Issued Financial Statements issued by the Company should not be relied upon. The Company intends to restate the Previously Issued Financial Statements to correct these errors by amending its Annual Report for the year ended February 28, 2011 and its Quarterly Reports for the three months ended May 31, 2011, six months ended August 31, 2011, and nine months ended November 30, 2011.

The errors in the Previously Issued Financial Statements relate to certain liabilities and the corresponding expenses incurred and material agreements executed by the Company throughout the fiscal years ended February 29, 2012 and February 28, 2011, that were not previously disclosed. 

As of the date of this Current Report, management of the Company has not had sufficient time to determine the impact of these errors on its financial condition, results of operations or cash flows reported in prior periods. Accordingly, the financial condition and results of operations disclosed in prior periods can no longer be relied upon.

FOR THE EFFECT OF THE RESTATEMENT OF THE FINANCIAL STATEMENTS OF THE COMPANY FOR THE YEAR ENDED FEBRUARY 28, 2011, PLEASE REFER TO THE AMENDMENTS TO OUR FORM 10-K FOR THE YEAR ENDED FEBRUARY 28, 2011 AND FORM 10-Q FOR THE PERIODS ENDED MAY 31, 2011, AUGUST 31, 2011 AND NOVEMBER 30, 2011, EXPECTED TO BE FILED BY JULY 20, 2012  OR A DATE SOON THEREAFTER.

The Company’s Board of Directors and management discussed the matters mentioned herein with Weaver, Martin & Samyn, LLC, the Company’s independent registered public accounting firm.
2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bioflamex Corp.


/s/ Kristian Schiorring
Kristian Schiorring
Chief Executive Officer
Date: June 21, 2012
3



I ONLY POST WHAT I PLAY
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation Launched into Avadel Pharmaceuticals Sale

Updated Category News Views 154

Understanding the Investigation into Avadel Pharmaceuticals Recent developments have sparked considerable interest concerning Avadel Pharmaceuticals plc (NASDAQ: AVDL). A prominent class action attorney, who is known for successfully recovering significant sums for shareholders, is now looking into the company's recent sale to Alkermes plc. This scrutiny raises important...

Continue Reading
GitLab's Recent Performance Sparks Mixed Analyst Reactions

Updated Category News Views 109

Investor Sentiment and GitLab's Performance Investor sentiment regarding technology stocks is characterized by volatility, particularly as firms like GitLab adjust to the evolving market landscape. In its latest earnings report, GitLab Inc. (NASDAQ: GTLB) has shown a remarkable ability to drive revenue amidst shifting investor expectations. Analysis of Financial Results...

Continue Reading
Innovative Imaging Technologies from Positron Corporation

Updated Category News Views 92

Introduction to Positron Corporation's Recent Achievements Positron Corporation, a pioneering name in molecular imaging technology, is making headlines with its remarkable achievements in the field of diagnostic imaging. They have recently announced the sale of two advanced imaging systems—the Attrius PET and the NeuSight PET-CT. These innovative technologies are set to...

Continue Reading
Potential Shifts in Fiscal Policy Could Impact Markets Significantly

Updated Category News Views 132

Implications of Trump's Fiscal Policy Shifts Recent discussions suggest that a potential return of Donald Trump to the presidency could be marked by a cabinet focused on fiscal restraint. Analysts at Macquarie have indicated that this possibility might disrupt the current trend known as the 'Trump trade,' potentially leading to lower Treasury yields. Understanding the...

Continue Reading
Implications of Trump's Proposal on Tesla's Future Growth

Updated Category News Views 173

Understanding the Impact of Legislation on Tesla Tesla Inc. (NASDAQ: TSLA) and its visionary CEO Elon Musk have been vocal about the implications of the recent "Big Beautiful Bill" supported by various lawmakers. This legislation stands to change the dynamics of the electric vehicle market by increasing costs for consumers while reducing available credits for electric...

Continue Reading